Unknown

Dataset Information

0

Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo.


ABSTRACT: Disruption of neurotransmitter vesicle dynamics (transport, capacity, release) has been implicated in a variety of neurodegenerative and neuropsychiatric conditions. Here, we report a novel mouse model of enhanced vesicular function via bacterial artificial chromosome (BAC)-mediated overexpression of the vesicular monoamine transporter 2 (VMAT2; Slc18a2). A twofold increase in vesicular transport enhances the vesicular capacity for dopamine (56%), dopamine vesicle volume (33%), and basal tissue dopamine levels (21%) in the mouse striatum. The elevated vesicular capacity leads to an increase in stimulated dopamine release (84%) and extracellular dopamine levels (44%). VMAT2-overexpressing mice show improved outcomes on anxiety and depressive-like behaviors and increased basal locomotor activity (41%). Finally, these mice exhibit significant protection from neurotoxic insult by the dopaminergic toxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), as measured by reduced dopamine terminal damage and substantia nigra pars compacta cell loss. The increased release of dopamine and neuroprotection from MPTP toxicity in the VMAT2-overexpressing mice suggest that interventions aimed at enhancing vesicular capacity may be of therapeutic benefit in Parkinson disease.

SUBMITTER: Lohr KM 

PROVIDER: S-EPMC4103325 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo.

Lohr Kelly M KM   Bernstein Alison I AI   Stout Kristen A KA   Dunn Amy R AR   Lazo Carlos R CR   Alter Shawn P SP   Wang Minzheng M   Li Yingjie Y   Fan Xueliang X   Hess Ellen J EJ   Yi Hong H   Vecchio Laura M LM   Goldstein David S DS   Guillot Thomas S TS   Salahpour Ali A   Miller Gary W GW  

Proceedings of the National Academy of Sciences of the United States of America 20140616 27


Disruption of neurotransmitter vesicle dynamics (transport, capacity, release) has been implicated in a variety of neurodegenerative and neuropsychiatric conditions. Here, we report a novel mouse model of enhanced vesicular function via bacterial artificial chromosome (BAC)-mediated overexpression of the vesicular monoamine transporter 2 (VMAT2; Slc18a2). A twofold increase in vesicular transport enhances the vesicular capacity for dopamine (56%), dopamine vesicle volume (33%), and basal tissue  ...[more]

Similar Datasets

| S-EPMC2812121 | biostudies-literature
| S-EPMC3061531 | biostudies-literature
| S-EPMC6757793 | biostudies-literature
| S-EPMC3186287 | biostudies-literature
| S-EPMC4896488 | biostudies-literature
| S-EPMC4489556 | biostudies-literature
| S-EPMC6340981 | biostudies-literature
| S-EPMC5013878 | biostudies-literature
| S-EPMC8170828 | biostudies-literature
| S-EPMC26633 | biostudies-literature